'Critical moment', AstraZeneca successfully blocks ex-executives from joining GSK

At a "crucial moment", AstraZeneca successfully blocked former executives from joining GSK

At a "crucial moment", AstraZeneca successfully blocked former executives from joining GSK

On September 1, former AstraZeneca executive Chris Sheldon was supposed to start his new job at GSK, but was arrested by a London court just hours before his appointment.

On Wednesday, AstraZeneca applied to the High Court in London for an emergency injunction to prevent Shelton from joining GSK the next day, according to the Financial Times and Bloomberg

Things have to go back to July this year, when AstraZeneca first sued the company's former vice president of investor relations, Chris Shelton, for violating a six-month non-compete by joining GSK before February.

If hired by GSK, Chris Shelton will serve as the company's senior vice president of commercial portfolio investments, and was scheduled to join on Sept.

"While we are disappointed by this temporary injunction, we remain confident that Dr Sheldon's position is firm and that he will be able to begin his new role at GSK after the main hearing in October

AstraZeneca has told multiple media that Shelton signed a non-compete agreement in 2021, and as a result, received more than 644,000 pounds ($774,090) in AstraZeneca's company shares

Shelton, however, has denied any wrongdoing and said he had disclosed to AstraZeneca in April his plans to change the company

In fact, the dispute between AstraZeneca and GlaxoSmithKline over an employee non-compete agreement is not the first
.

In fact, the dispute between AstraZeneca and GlaxoSmithKline over an employee non-compete agreement is not the first
.